Iktos AI Secures $2.5M to Accelerate Next-Generation AI-Driven Drug Discovery

Iktos AI is thrilled to announce that it has successfully raised $2,500,000 in its latest funding round to further accelerate its leadership in AI-driven solutions for medicinal chemistry and small molecule drug design. As a pioneering force in the intersection of artificial intelligence and robotics, Iktos leverages its groundbreaking generative AI technology to design molecules optimized in silico, fulfilling the complex criteria of modern drug discovery projects. With its pioneering SaaS platforms—Makya™ for generative drug design and Spaya™ for retrosynthesis—as well as its unique Iktos Robotics, the company significantly enhances productivity in pharmaceutical R&D, enabling a transformative acceleration of the Design-Make-Test-Analyze cycle. This latest round not only reinforces investor confidence following previous milestones such as a 15.5M€ Series A financing round in March 2023 and the strategic acquisition of Synsight in July 2024, but it also provides the resources necessary to expand and refine its innovative platforms. The new funds will be strategically deployed to drive further advancements in generative design algorithms, expand the capabilities of its robotics-driven automation platform, and support ongoing strategic collaborations with leading pharma companies. This infusion of capital will also bolster Iktos' efforts to accelerate the development of its in-house pipeline of drug candidates, particularly in the fields of oncology, auto-immune, and inflammatory diseases. In embracing this new phase of growth, Iktos AI reaffirms its commitment to revolutionizing drug discovery and strengthening its role as an indispensable partner in enhancing R&D productivity. With this fresh capital, the company is well-positioned to confront current challenges in medicinal chemistry and create a substantial impact on the future of healthcare innovation.